Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
42. Cavalca V, Cighetti G, Bamonti F, et al. Oxidative stress and homocystein in coronary artery disease. Clin Chemistry 2001; 47: 887— 892.
43. Key NS, McGlennen RC. Hyperhomo-cysteinemia and thrombophilia. Arch Pathol Lab Med 2002; 126: 1367—1375.
44. Ungvari Z, Csiszar A, Edwards JG, et al. Increased superoxide production in coronart
arteries in hyperhomocysteinemia. Role of tumor necrosis factor-а, NAD(P)H oxidase, abd inducible nitric oxide synthase. Atheroscl. Thromb Vasc Biol 2003; 23: 418—424.
45. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001; 104: 503—516.
46. Barter P. Effects of inflammation on high-density lipoproteins. Arteriol Thromb Vasc Biol 2002; 22:1062—1064.
47. Navab M, Berliner JA, Subbanagounder G, et al. HDL and inflammatory response induced by LDL-derived oxidized phospholipids. Arteriol Thromb Vasc Biol 2001; 21: 481—488.
48. Hansen GK. Immune mechanisms in atherosclerosis. Arterioscler Thromm Vasc Biol 2001; 21: 1876—1890.
49. Van der Thusen JH, Kuiper J, van Berrel TJC, Biessen EAI. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacology Rev 2003; 55: 133—166.
50. Medzhotov R, Janeway C. Innate Immunity. N Engl J Med 2000; 343: 338—344.
51. Kiechl S, Lorenz E, Reindl M, et al. Tolllike receptor 4 polymorphism and atherogenesis. New Engl J Med 2002; 347: 185—192.
52. Daugherty A, Rateri D. T lymphocytes in atherosclerosis. The Yin-Yang of Th1 and Th2 influence on ledion formation Circ Res 2002; 90: 1039—1040.
53. Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Sol Sherry lecture in thrombosis. Molecular events in acute inflammation. Arterioscler Thromb Vasc Biol 2002; 22: 727— 733.
54. Warne JP. Tumor necrosis factor a: a key regulator of adipose tissue mass J Endocrinol 2003; 377: 351—355.
55. Bazzoni F., Beutler B. Tumor necrosis factor ligand and receptor families. N. Engl. J. Med., 1996; 334:1717—1725.
56. Zhang M, Tracey KJ. Tumor necrosis factor. In: Thompson AW, er. The cytokine handbook, 3rd ed. New York. Academic press, 1998; 515—548.
57. Dinarello CA, Moldawer LL. Proinflam-matory and anti-inflammatory cytokines in rheumatoid arthritis. A primar for clinicians. Third edition. 2002; Amgen Inc. 351 p.
58. Schreyer SA, Peschon JJ, LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor
SHS-OOO4.qxd 21.11.2006 16:56 Page 146"
Насонов Е.Л. Антифосфолипидный синдром.
necrosis factor receptor p55. J Biol Chem. 1996; 271: 26174—26178.
59. Zimmerman M, Selzman C, Reznikov LL, et al. Lack of TNF-a attenuates untimal hyperplasia after mouse carotide artery injury. Am J Physiol Reg Integrat Comp Physiol 2002; 283: R505—R512.
60. Ridker PM, Rifai N, Pfefer M, et al. Elevation of tumor necrosis factor-a and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149—2153.
61. Elkind MS, Cheng J, Boden-Albata B., et al. Tumor necrosis factor levels are associated with carotid atherosclerosis. Stroke 2002; 33: 31—38.
62. Thrift AG. Association between tumor necrosis factor receptor levels and carotide atherosclerosis: is the association limited to younger individuals? Stroke 2002; 33: 37—38
63. Blann AD, McCollum CN. Increased levels of tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation 22: 483—491.
64. Chia S, Qadan M, Newton R, et al. Intra-arterial tumor necrosis factor-a impairs endotheli-um-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans Arteriol Thromb Vascular Biol 2003; 23: 659—665.
65. Hurlimann D, Forster A, Noll G, et al. Antitumor necrosis factor-a treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184—2187.
66. Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a Th1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998; 101: 1717—1725.
67. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: 17—24.
68. Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol 1998; 9: 397—405.
69. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circulation Res 2001; 89: 1092—1103.
70. Andre P, Nannizzi-Alaimp L, Prasard SK, Philips DR. Platelet-derived CD40L. The switch-hitting player of cardiovascular disease. Circulation 2002; 106: 896—899.
71. Vaarala O. Immunology of atherosclerosis. In Vascular manifestations of systemic autoimmune disease. Ed, RA Asherson, R Cervera. CRC 2002; 61—70.
72. Lozarda C, Levine RI, Hui M, et al. Identification on C1q as the heart-stable serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules I. Proc Natl Acad Sci USA 1995; 92: 8378—8382.
